Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Current Deferred Revenue (2024 - 2025)

Camp4 Therapeutics (CAMP) has disclosed Current Deferred Revenue for 2 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 2338.18% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, up 2338.18% year-over-year, with the annual reading at $9.4 million for FY2025, 2338.18% up from the prior year.
  • Current Deferred Revenue hit $9.4 million in Q4 2025 for Camp4 Therapeutics, up from $385000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $9.4 million in Q4 2025 to a low of $385000.0 in Q4 2024.